Moreover, there is debate whether this is independent from an anti-MM effect of bortezomib: although serum sclerostin (inhibiting BF) is downregulated independent of an anti-MM effect [13], the increase in the number of osteoblasts was found only in responding patients [4]. This evidence concerns the gene SOST and Miyoshi myopathy.